Search

Your search keyword '"Pol Stanislas"' showing total 2,116 results
Start Over Author "Pol Stanislas"
2,116 results on '"Pol Stanislas"'

252. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV

Author

Casrouge, Armanda, Decalf, Jeremie, Ahloulay, Mina, Lababidi, Cyril, Mansour, Hala, Vallet-Pichard, Anais, Mallet, Vincent, Mottez, Estelle, Mapes, James, Fontanet, Arnaud, Pol, Stanislas, and Albert, Matthew L.

Subjects
Diagnosis, Drug therapy, Physiological aspects, Research, Chemokines -- Physiological aspects -- Research, Proteases -- Physiological aspects -- Research, Hepatitis C -- Diagnosis -- Research -- Drug therapy
Abstract

Introduction There are nearly 170 million HCV-infected individuals worldwide (1). Many studies have explored the mechanisms by which the immune system is capable of mediating viral clearance (2). Although an [...], Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide. Current treatment for chronic infection is a combination of pegylated IFN-[α.sub.2] and ribavirin (RBV); however, this treatment is effective in fewer than 50% of patients infected with HCV genotype 1 or 4. Recent studies identified the chemokine CXCL10 (also known as IP-10) as an important negative prognostic biomarker. Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counterintuitive that this chemokine correlates with therapeutic nonresponsiveness. Herein, we offer new insight into this paradox and provide evidence that CXCL10 in the plasma of patients chronically infected with HCV exists in an antagonist form, due to in situ amino-terminal truncation of the protein. We further demonstrated that dipeptidyl peptidase IV (DPP4; also known as CD26), possibly in combination with other proteases, mediates the generation of the antagonist form(s) of CXCL10. These data offer what we believe to be the first evidence for CXCL10 antagonism in human disease and identify a possible factor contributing to the inability of patients to clear HCV.

Published
2011
Full Text
View/download PDF

253. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study

Author

Michot, Jean-Marie, Canioni, Danielle, Driss, Henda, Alric, Laurent, Cacoub, Patrice, Suarez, Felipe, Sibon, David, Thieblemont, Catherine, Dupuis, Jehan, Terrier, Benjamin, Feray, Cyrille, Tilly, Hervé, Pol, Stanislas, Leblond, Véronique, Settegrana, Catherine, Rabiega, Pascaline, Barthe, Yoann, Hendel-Chavez, Houria, Nguyen-Khac, Florence, Merle-Béral, Hélène, Berger, Françoise, Molina, Thierry, Charlotte, Frédéric, Carrat, Fabrice, Davi, Frédéric, Hermine, Olivier, and Besson, Caroline

Published
2015
Full Text
View/download PDF

256. Interferon (gamma) receptor 2 gene variants are associated with liver fibrosis with chronic hepatitis C infection

Author

Nalpas, Bertrand, Lavialle-meziani, Roubila, Plancoulaine, Sabine, Jouanguy, Emmanuelle, Nalpas, Antoine, Munteanu, Mona, Charlotte, Frederic, Ranque, Brigitte, Patin, Etienne, Heath, Simon, Fontaine, Helene, Vallet-Pichard, Anais, Pontoire, Dominique, Bourliere, Marc, Casanova, Jean-Laurent, Lathrop, Mark, Brechot, Christian, Poynard, Thierry, Matsuda, Fumihiko, Pol, Stanislas, and Abel, Laurent

Subjects
Cystic fibrosis -- Risk factors, Cystic fibrosis -- Genetic aspects, Cystic fibrosis -- Research, Hepatitis C -- Complications and side effects, Hepatitis C -- Research, Interferon gamma -- Genetic aspects, Interferon gamma -- Research, Genetic variation -- Research, Health
Published
2010

257. Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study (Final results, Parts A and B): 236

Author

Sulkowski, Mark S., Hezode, Christophe, Gerstoft, Jan, Vierling, John M., Mallolas, Josep, Pol, Stanislas, Kugelmas, Marcelo, Murillo, Abel, Weis, Nina, Nahass, Ronald, Shibolet, Oren, Serfaty, Lawrence, Bourlière, Marc, DeJesus, Edwin, Zuckerman, Eli., Dutko, Frank, Howe, Anita Y., Shaughnessy, Melissa, Hwang, Peggy, Wahl, Janice, Robertson, Michael, and Haber, Barbara A.

Published
2014

258. An Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledip-asvir/Sofosbuvir with or without Ribavirin: 82

Author

Bourlière, Marc, Sulkowski, Mark S., Omata, Masao, Zeuzem, Stefan, Feld, Jordan J., Lawitz, Eric, Marcellin, Patrick, Hyland, Robert H., Ding, Xiao, Yang, Jenny C., Knox, Steven J., Pang, Phillip S., Subramanian, Mani, Symonds, William T., McHutchison, John G., Mangia, Alessandra, Gane, Edward J., Reddy, Rajender K., Mizokami, Masashi, Pol, Stanislas, and Afdhal, Nezam H.

Published
2014

260. All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection

Author

Wyles, David L., Rodriguez-Torres, Maribel, Lawitz, Eric, Shiffman, Mitchell L., Pol, Stanislas, Herring, Robert W., Massetto, Benedetta, Kanwar, Bittoo, Trenkle, James D., Pang, Phil S., Zhu, Yanni, Mo, Hongmei, Brainard, Diana M., Subramanian, Mani G., McHutchison, John G., Habersetzer, François, and Sulkowski, Mark S.

Published
2014
Full Text
View/download PDF

261. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

Author

Hezode, Christophe, Forestier, Nicole, Dusheiko, Geoffrey, Ferenci, Peter, Pol, Stanislas, Goeser, Tobias, Bronowicki, Jean-Pierre, Bourliere, Marc, Gharakhanian, Shahin, Bengtsson, Leif, McNair, Lindsay, George, Shelley, Kieffer, Tara, Kwong, Ann, Kauffman, Robert S., Alam, John, Pawlotsky, Jean-Michel, and Zeuzem, Stefan

Subjects
Hepatitis C -- Drug therapy, Hepatitis C -- Care and treatment, Peginterferon alfa-2a -- Usage, Peginterferon alfa-2a -- Health aspects, Ribavirin -- Usage, Ribavirin -- Health aspects, Drug therapy, Combination
Abstract

The effects of the various combinations of telaprevir, peginterferon alfa-2a and ribavirin on the treatment of the patients with hepatitis C virus (HCV) genotype 1 infection are analyzed. The combination of telaprevir and peginterferon without the presence of ribavirin is shown to lead to the lowest response rates by the patients.

Published
2009

262. Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies 166

Author

Kartasheva-Ebertz, Daria, Gaston, Jesintha, Lair-Mehiri, Loriane, Massault, Pierre-Philippe, Scatton, Olivier, Vaillant, Jean-Christophe, Morozov, Vladimir Alexei, Pol, Stanislas, Lagaye, Sylvie, Immunobiologie des Cellules dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Chirurgie digestive, hépato-biliaire et endocrinienne [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Robert Koch Institute [Berlin] (RKI), INSERM, Institut Pasteur, AP-HP, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Hepatitis C virus, [SDV]Life Sciences [q-bio], Drugs, Alcoholic liver disease, Human liver fibrosis, Nonalcoholic steatohepatitis, Ex vivo model
Abstract

International audience; Background: Liver fibrosis can result in end-stage liver failure and death.Aim: To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional ex vivo liver slice (LS) model.Methods: Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score) were collected from patients after liver resection. Human liver slices (HLS) were cultivated for up to 21 days. Hepatitis C virus (HCV) infection, alcohol (ethanol stimulation) and steatosis (palmitate stimulation) were examined in fibrotic (F2 to F4) liver slices infected (or not) with HCV. F0-F1 HLS were used as controls. At day 0, either ursodeoxycholic acid (choleretic and hepatoprotective properties) and/or α-tocopherol (antioxidant properties) were added to standard of care on HLS and fibrotic liver slices, infected (or not) with HCV. Expression of the biomarkers of fibrosis and the triglyceride production were checked by quantitative reverse transcription polymerase chain reaction and/or enzyme-linked immunosorbent assay.Results: The cultures were viable in vitro for 21 days allowing to study fibrosis inducers and to estimate the effect of anti-fibrotic drugs. Expression of the biomarkers of fibrosis and the progression to steatosis (estimated by triglycerides production) was increased with the addition of HCV and /or ethanol or palmitate. From day 15 of the follow-up studies, a significant decrease of both transforming growth factor β-1 and Procol1A1 expression and triglycerides production was observed when a combined anti-fibrotic treatment was applied on HCV infected F2-F4 LS cultures.Conclusion: These results show that the human three dimensional ex vivo model effectively reflects the in vivo processes in damaged human liver (viral, alcoholic, nonalcoholic steatohepatitis liver diseases) and provides the proof of concept that the LS examined model permits a rapid evaluation of new anti-fibrotic therapies when used alone or in combination.

Published
2021
Full Text
View/download PDF

263. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply

Author

Pol, Stanislas, Luzivika Nzinga, Clovis, Fontaine, Hélène, Carrat, Fabrice, Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de santé publique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Inserm-ANRS, ANR, DGS and MSD, Janssen, Gilead, Abbvie, BMS, Roche, HAL-SU, Gestionnaire, CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
MESH: Antiviral Agents, MESH: Guanine, MESH: Hepatitis B virus, MESH: Humans, MESH: Tenofovir, MESH: Hepatitis B, Chronic, MESH: Liver Neoplasms, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, MESH: Carcinoma, Hepatocellular
Abstract

International audience

Published
2021
Full Text
View/download PDF

264. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort

Author

Pol, Stanislas, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Chevalier, Caroline, Hubert, Isabelle, Goepfert, Pierre, Lannes, Adrien, Lunel, François, Boursier, Jérôme, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Legendre, Amandine, Chermak, Faiza, Irlès-Depé, Marie, Ahmed, Si Nafa Si, Ansaldi, Christelle, Amara, Nisserine Ben, Oules, Valérie, Dunette, Jacqueline, Anty, Rodolphe, Gelsi, Eve, Truchi, Régin, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, Dieuleveult, Barbara De, Goin, Héloïse, Labarrière, Damien, Potier, Pascal, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverin, Monard, Rym, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F, Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphani, Ripault, Marie Pierre, Bureau, Christophe, Launay, Sarah, Peron, Jean Marie, Robic, Marie Angèl, Tarallo, Lé, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, E Montialoux, Hélè, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, E Angoulevant, Bénédic, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Vallée, Jean-Charles Duclos, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldin, Muti, Léo, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastie, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièl, Saillard, Eric, Lafrance, Marie-José, Nzinga, Clovis Luzivika, Dorival, Céline, Zoulim, Fabien, Cagnot, Carole, Decaens, Thomas, Thabut, Dominique, Asselah, Tarik, Mathurin, Philippe, Ganne, Nathalie, Samuel, Didier, Habersetzer, Françoi, Bronowicki, Jean-Pierre, Guyader, Dominique, Rosa, Isabelle, Leroy, Vincent, Chazouilleres, Olivier, Ledinghen, Victor De, Bourliere, Marc, Causse, Xavier, Cales, Paul, Metivier, Sophie, Loustaud-Ratti, Véroniqu, Abergel, Armand, Fontaine, Hélène, Carrat, Fabrice, Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
MESH: Antiviral Agents, MESH: Guanine, MESH: Hepatitis B virus, MESH: Humans, MESH: Tenofovir, MESH: Hepatitis B, Chronic, MESH: Liver Neoplasms, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Carcinoma, Hepatocellular, MESH: Prospective Studies, MESH: Treatment Outcome
Abstract

International audience; Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications.Aim: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort.Methods: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW).Results: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively.Conclusion: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients.Trial registration number: NCT019553458.

Published
2021
Full Text
View/download PDF

265. Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

Author

Barré, Tangui, Pol, Stanislas, Ramier, Clémence, Di Beo, Vincent, Carrat, Fabrice, Bureau, Morgane, Bourlière, Marc, Dorival, Céline, Serfaty, Lawrence, Asselah, Tarik, Boursier, Jérôme, Marcellin, Fabienne, Carrieri, Patrizia, Fontaine, Hélène, Protopopescu, Camelia, Alric, Laurent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Zoulim, Fabien, Maynard, Marianne, Bai, Roxane, Hucault, Lucie, Bailly, François, Raffi, François, Billaud, Eric, Boutoille, David, Lefebvre, Maeva, André-Garnier, Elisabeth, Cales, Paul, Hubert, Isabelle, Lannes, Adrien, Lunel, Françoise, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Rousseaud, Emilie, Vallet-Pichard, Anaïs, Sogni, Philippe, Ledinghen, Victor De, Foucher, Juliette, Hiriart, Jean-Baptiste, M'Bouyou, Jancell, Irlès-Depé, Marie, Si Ahmed, Si Nafa, Oules, Valérie, Tran, Albert, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Thabut, Dominique, Hammeche, Saloua, Moussali, Joseph, Causse, Xavier, Dieuleveult, Barbara De, Ouarani, Brahim, Labarrière, Damien, Ganne, Nathalie, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverine, Ulker, Betul, Guyader, Dominique, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Habersetzer, François, Baumert, Thomas, Doffoel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Bronowicki, Jean-Pierre, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Larrey, Dominique, Meszaros, Magda, Metivier, Sophie, Bureau, Christophe, Morales, Thibault, Peron, Jean Marie, Robic, Marie Angèle, Decaens, Thomas, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Riachi, Ghassan, Goria, Odile, Paris, Fatima, Montialoux, Hélène, Leroy, Vincent, Amaddeo, Giuliana, Varaut, Anne, Simoes, Mélanie, Amzal, Rachida, Chazouillières, Olivier, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Samuel, Didier, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Abergel, Armand, Reymond, Maud, Brigitte, Chanteranne, Benjamin, Buchard, Muti, Léon, Geist, Claire, Conroy, Guillaume, Riffault, Raphaëlle, Rosa, Isabelle, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Loustaud-Ratti, Véronique, Carrier, Paul, Debette-Gratien, Maryline, Mathurin, Philippe, Lassailly, Guillaume, Lemaitre, Elise, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Minello, Anne, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, d'Alteroche, Louis, Barbereau, Didier, Nicolas, Charlotte, Elkrief, Laure, Jaillais, Anaïs, Gournay, Jérôme, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Portal, Isabelle, Gelu-Simeon, Moana, Saillard, Eric, Lafrance, Marie-Josée, Catherine, Lucie, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépato-gastro-entérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hôpital de Hautepierre [Strasbourg], Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), and BOURGEAIS, Véronique

Subjects
Hepatitis B virus, medicine.medical_specialty, Cirrhosis, [SDV]Life Sciences [q-bio], Aucun, Overweight, medicine.disease_cause, Virus, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Internal medicine, medicine, Humans, Pharmacology (medical), Obesity, ComputingMilieux_MISCELLANEOUS, Cannabis, 030304 developmental biology, Pharmacology, 0303 health sciences, biology, Cannabinoids, business.industry, Liver Neoplasms, Hepatitis B, biology.organism_classification, medicine.disease, digestive system diseases, 3. Good health, [SDV] Life Sciences [q-bio], Complementary and alternative medicine, Hepatocellular carcinoma, Cohort, cannabis, obesity, overweight, socioeconomic status, 030211 gastroenterology & hepatology, medicine.symptom, business
Abstract

International audience; Background: Chronic hepatitis B virus (HBV) infection may evolve into cirrhosis and hepatocellular carcinoma, and this progression may be accelerated by specific risk factors, including overweight and obesity. Although evidence for a protective effect of cannabis use on elevated body weight has been found for other populations, no data are available for HBV-infected patients.Aims: We aimed to identify risk factors (including cannabis use) for overweight and obesity in patients with HBV chronic infection.Methods: Using baseline data from the French ANRS CO22 Hepather cohort, we performed two separate analyses, one using “central obesity” (based on waist circumference) and the other “overweight” and “obesity” (based on body mass index) as outcomes. Logistic and multinomial regressions were used to model central obesity and overweight/obesity, respectively.Results: Among the 3706 patients in the study population, 50.8% had central obesity, 34.7% overweight, and 14.4% obesity. After multivariable adjustment, current cannabis use was associated with a 59% lower risk of central obesity compared with no lifetime use (adjusted odds ratio [95% CI]: 0.41 [0.24 to 0.70]). It was also associated with a 54% and 84% lower risk of overweight (adjusted relative risk ratio [95% CI]: 0.46 [0.27 to 0.76]) and obesity (0.16 [0.04 to 0.67]), respectively.Conclusions: Cannabis use was associated with lower risks of overweight and obesity in patients with HBV chronic infection. Future studies should test whether these potential benefits of cannabis and cannabinoid use translate into reduced liver disease progression in this high-risk population.

Published
2021
Full Text
View/download PDF

266. Clinical Outcomes After Treatment With Direct Antiviral Agents: Beyond The Virological Response in Patients With Previous HCV-Related Decompensated Cirrhosis

Author

PAGEAUX, Georges-Philippe, primary, NZINGA, Clovis LUSIVIKA, additional, GANNE, Nathalie, additional, SAMUEL, Didier, additional, DORIVAL, Céline, additional, ZOULIM, Fabien, additional, CAGNOT, Carole, additional, DECAENS, Thomas, additional, THABUT, Dominique, additional, ASSELAH, Tarik, additional, MATHURIN, Philippe, additional, HABERSETZER, François, additional, BRONOWICKI, Jean-Pierre, additional, GUYADER, Dominique, additional, ROSA, Isabelle, additional, LEROY, Vincent, additional, CHAZOUILLERES, Olivier, additional, DE LEDINGHEN, Victor, additional, BOURLIERE, Marc, additional, CAUSSE, Xavier, additional, CALES, Paul, additional, METIVIER, Sophie, additional, LOUSTAUD-RATTI, Véronique, additional, RIACHI, Ghassan, additional, ALRIC, Laurent, additional, GELU-SIMEON, Moana, additional, MINELLO, Anne, additional, GOURNAY, Jérôme, additional, GEIST, Claire, additional, TRAN, Albert, additional, ABERGEL, Armand, additional, PORTAL, Isabelle, additional, D’ALTEROCHE, Louis, additional, RAFFI, François, additional, FONTAINE, Hélène, additional, CARRAT, Fabrice, additional, and POL, Stanislas, additional

Published
2021
Full Text
View/download PDF

267. Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients

Author

Hollande, Clémence, primary, Boussier, Jeremy, additional, Mottez, Estelle, additional, Bondet, Vincent, additional, Buivan, Tan Phuc, additional, Charbit, Bruno, additional, Llibre, Alba, additional, Charlotte, Frédéric, additional, Savier, Eric, additional, Scatton, Olivier, additional, Duffy, Darragh, additional, Albert, Matthew, additional, Mallet, Vincent, additional, and Pol, Stanislas, additional

Published
2021
Full Text
View/download PDF

268. Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort).

Author

Barré, Tangui, Pol, Stanislas, Ramier, Clémence, Di Beo, Vincent, Carrat, Fabrice, Bureau, Morgane, Bourlière, Marc, Dorival, Céline, Serfaty, Lawrence, Asselah, Tarik, Boursier, Jérôme, Marcellin, Fabienne, Carrieri, Patrizia, Fontaine, Hélène, Protopopescu, Camelia, Alric, Laurent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, and Zoulim, Fabien

Published
2022
Full Text
View/download PDF

269. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors

Author

Bani-Sadr, Firouze, Lapidus, Nathanael, Bedossa, Pierre, De Boever, Corinne Merle, Perronne, Christian, Halfon, Philippe, Pol, Stanislas, Carrat, Fabrice, and Cacoub, Patrice

Subjects
Fibrosis -- Risk factors, Hepatitis C -- Complications and side effects, Ribavirin -- Dosage and administration, Interferon -- Dosage and administration, Health, Health care industry
Published
2008

270. The IL-17A and IL-22 cytokines like triggers of human liver fibrosis

Author

Kartasheva-Ebertz, Daria, Gaston, Jesintha, Massault, Pierre-Philippe, Gaujoux, Sébastien, Scatton, Olivier, Vaillant, Jean-Christophe, Morozov, Vladimir, Pol, Stanislas, Lagaye, Sylvie, Université Paris Cité (UPCité), Immunobiologie des Cellules dendritiques, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Chirurgie digestive, hépato-biliaire et endocrinienne [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Robert Koch Institute [Berlin] (RKI), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris (UP), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0303 health sciences, 03 medical and health sciences, 0302 clinical medicine, Hepatology, 030211 gastroenterology & hepatology, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030304 developmental biology
Abstract

International audience

Published
2020
Full Text
View/download PDF

271. Rapid and early virological response to chronic hepatitis C treatment with IFN (alpha)2b or PEG-IFN (alpha)2b plus ribavirin in HIV/HCV co-infected patients

Author

Payan, Christopher, Pivert, Adeline, Morand, Patrice, Fafi-Kremer, Samira, Carrat, Fabrice, Pol, Stanislas, Cacoub, Patrice, Perronne, Christian, and Lunel, Francoise

Subjects
Hepatitis C -- Drug therapy, Hepatitis C -- Research, Hepatitis C -- Patient outcomes, Ribavirin -- Usage, Ribavirin -- Research, Ribavirin -- Health aspects, HIV patients -- Drug therapy, HIV patients -- Patient outcomes, Drug therapy -- Patient outcomes, Health
Published
2007

273. Impact des nouveaux traitements (AAD) de l’hépatite C dans la population générale et les populations à risque : étude réalisée en France à partir des données du SNDS sur la période 2015-2019

Author

Rabiéga, Pascaline, primary, Pol, Stanislas, additional, Fouad, Fayssoil, additional, Rodriguez, Ingrid, additional, Lada, Olivier, additional, Lemaitre, Magali, additional, Benabadji, Elias, additional, and Roudot-Thoraval, Françoise, additional

Published
2021
Full Text
View/download PDF

275. LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?

Author

Barat, Maxime, primary, Nguyen, Thi Thuy Linh, additional, Hollande, Clémence, additional, Coty, Jean-Baptiste, additional, Hoeffel, Christine, additional, Terris, Benoit, additional, Dohan, Anthony, additional, Mallet, Vincent, additional, Pol, Stanislas, additional, and Soyer, Philippe, additional

Published
2021
Full Text
View/download PDF

276. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients

Author

Mallet, Vincent, primary, Bock, Kilian, additional, Mandengue, Paul Doumbe, additional, Dufour, Nicolas, additional, Voigtlaender, Torsten, additional, Ricard, Jean-Damien, additional, Isnard, Pierre, additional, Frochot, Vincent, additional, Letavernier, Emmanuel, additional, Moga, Lucile, additional, Landrieux, Amandine, additional, Rautou, Pierre-Emmanuel, additional, Pons-Kerjean, Nathalie, additional, Vallet-Pichard, Anaïs, additional, Chouchana, Laurent, additional, Gernez, Coralie, additional, Burger, Carole, additional, Scemla, Anne, additional, de Tymoski, Christian, additional, Depret, François, additional, Dudoignon, Emmanuel, additional, Lamhaut, Lionel, additional, Flicoteau, Rémi, additional, Rousseau, Géraldine, additional, Duong Van Huyen, Jean-Paul, additional, Correas, Jean-Michel, additional, Wedemeyer, Heiner, additional, and Pol, Stanislas, additional

Published
2021
Full Text
View/download PDF

279. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

Author

Berger, Arthur, primary, Ravaioli, Federico, additional, Farcau, Oana, additional, Festi, Davide, additional, Stefanescu, Horia, additional, Buisson, François, additional, Nahon, Pierre, additional, Bureau, Christophe, additional, Ganne-Carriè, Nathalie, additional, Berzigotti, Annalisa, additional, de Ledinghen, Victor, additional, Petta, Salvatore, additional, Calès, Paul, additional, Huvelin, Sylvie Sacher, additional, Valla, Dominique, additional, Olivier, Anne, additional, Oberti, Frédéric, additional, Boursier, Jérôme, additional, Galmiche, Jean Paul, additional, Vinel, Jean Pierre, additional, Duburque, Clotilde, additional, Attar, Alain, additional, Archambeaud, Isabelle, additional, Benamouzig, Robert, additional, Gaudric, Marianne, additional, Luet, Dominique, additional, Couzigou, Patrice, additional, Planche, Lucie, additional, Coron, Emmanuel, additional, Hiriart, Jean-Baptiste, additional, Chermak, Faiza, additional, Charbonnier, Maude, additional, Marcellin, Patrick, additional, Guyader, Dominique, additional, Pol, Stanislas, additional, Fontaine, Hélène, additional, Larrey, Dominique, additional, De Lédinghen, Victor, additional, Ouzan, Denis, additional, Zoulim, Fabien, additional, Roulot, Dominique, additional, Tran, Albert, additional, Bronowicki, Jean-Pierre, additional, Zarski, Jean-Pierre, additional, Leroy, Vincent, additional, Riachi, Ghassan, additional, Péron, Jean-Marie, additional, Alric, Laurent, additional, Bourlière, Marc, additional, Mathurin, Philippe, additional, Dharancy, Sebastien, additional, Blanc, Jean-Frédéric, additional, Abergel, Armand, additional, Serfaty, Lawrence, additional, Mallat, Ariane, additional, Grangé, Jean-Didier, additional, Attali, Pierre, additional, Bacq, Yannick, additional, Wartelle, Claire, additional, Dao, Thông, additional, Benhamou, Yves, additional, Pilette, Christophe, additional, Silvain, Christine, additional, Christidis, Christos, additional, Capron, Dominique, additional, Thiefin, Gérard, additional, Hillaire, Sophie, additional, and Di Martino, Vincent, additional

Published
2021
Full Text
View/download PDF

280. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment

Author

Bani-Sadr, Firouze, Carrat, Fabrice, Rosenthal, Eric, Piroth, Lionel, Morand, Patrice, Lunel-Fabiani, Francoise, Bonarek, Mojgan, de Verdiere, Nathalie Colin, Pialoux, Gilles, Cacoub, Patrice, Pol, Stanislas, and Perronne, Christian

Subjects
Hepatitis C virus -- Risk factors, Hepatitis C virus -- Diagnosis, Hepatitis C virus -- Drug therapy, HIV infection -- Risk factors, HIV infection -- Diagnosis, HIV infection -- Drug therapy, Interferon -- Dosage and administration, Ribavirin -- Dosage and administration, Health, Health care industry
Published
2005

281. Risk factor for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy

Author

Bani-Sadr, Firouze; Carrat, Fabrice; Pol, Stanislas, Hor, Ravy; Rosenthal, Eric; Goujard, Cecile; Morand, Patrice, Lunel-Fabiani, Francoise; Salmon-Ceron, Dominique, Piroth, Lionel; Pialoux, Gilles, and Bentata, Michele; Cacoub, Patrice; Perronne, Christian

Subjects
Hepatitis C virus -- Drug therapy, HIV infection -- Drug therapy, Didanosine -- Dosage and administration, Ribavirin -- Dosage and administration, Health
Abstract

The incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy are evaluated. The results suggest that coadminstration of ribavirin and didanosine should be avoided, and if unavoidable, the patients should be monitored closely for mitochondrial toxicity.

Published
2005

282. Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

Author

Kamar, Nassim, Izopet, Jacques, Tripon, Simona, Bismuth, Michael, Hillaire, Sophie, Dumortier, Jérôme, Radenne, Sylvie, Coilly, Audrey, Garrigue, Valérie, DʼAlteroche, Louis, Buchler, Matthias, Couzi, Lionel, Lebray, Pascal, Dharancy, Sebastien, Minello, Anne, Hourmant, Maryvonne, Roque-Afonso, Anne-Marie, Abravanel, Florence, Pol, Stanislas, Rostaing, Lionel, and Mallet, Vincent

Published
2014
Full Text
View/download PDF

285. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients

Author

Carrat, Fabrice, Bani-Sadr, Firouze, Pol, Stanislas, Rosenthal, Eric, Lunel-Fabiani, Francoise, Benzekri, Asmae, Perronne, Christian, Cacoub, Patrice, Morand, Patrice, Goujard, Cecile, Degott, Claude, Lionel Salmon-Ceron, Dominique, and Pialouz, Gilles

Subjects
Hepatitis C -- Drug therapy, Ribavirin -- Dosage and administration, HIV infection -- Drug therapy
Abstract

The study conducted to investigate the safety and efficacy of peginterferon alfa-2b plus ribavirin against standard interferon alfa-2b plus ribavirin in HIV-HCV (hepatitis C virus) coinfected patients is presented. It is found that in combination with ribavirin, treatment with peginteferon alfa-2b is more effective than standard interferon alfa-2b for HCV infection in HIV-infected patients.

Published
2004

288. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

Author

Sulkowski, Mark S., Bourlière, Marc, Bronowicki, Jean-Pierre, Asselah, Tarik, Pawlotsky, Jean-Michel, Shafran, Stephen D., Pol, Stanislas, Mauss, Stefan, Larrey, Dominique, Datsenko, Yakov, Stern, Jerry O., Kukolj, George, Scherer, Joseph, Nehmiz, Gerhard, Steinmann, Gerhard G., and Böcher, Wulf O.

Published
2013
Full Text
View/download PDF

291. Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease.

Author

Wenyi Gu, de Lédinghen, Victor, Aubé, Christophe, Krag, Aleksander, Strassburg, Christian, Castéra, Laurent, Dumortier, Jérôme, Friedrich-Rust, Mireen, Pol, Stanislas, Grgurevic, Ivica, Zeleke, Yasmin, Praktiknjo, Michael, Schierwagen, Robert, Klein, Sabine, Francque, Sven, Gottfriedová, Halima, Sporea, Ioan, Schindler, Philipp, Rennebaum, Florian, and Brol, Maximilian Joseph

Subjects
RISK assessment, VIRAL hepatitis, EARLY detection of cancer, DISEASE prevalence, DESCRIPTIVE statistics, DECISION making in clinical medicine, LIVER diseases, CHRONIC diseases, CONFIDENCE intervals, HEPATOCELLULAR carcinoma, ALGORITHMS, PATIENT aftercare, DISEASE risk factors, DISEASE complications
Abstract

Background Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the risk of HCC development in ACLD. Methods From 3016 patients with ACLD screened in 17 European and Chinese centers, 2340 patients with liver stiffness measurement (LSM) determined using different techniques (two-dimensional shear-wave elastography [2D-SWE], transient elastography, and point shear-wave elastography) and with different disease severities were included. Cox regression was used to explore risk factors for HCC. We used these data to create an algorithm, named PLEASE, but referred to in this manuscript as “the algorithm”; the algorithm was validated in internal and two external cohorts across elastography techniques. Results HCC developed in 127 (5.4%) patients during follow-up. LSM by 2D-SWE (hazard ratio: 2.28) was found to be associated with developing HCC, alongside age, sex, etiology, and platelet count (C-index: 0.8428). We thus established the algorithm with applicable cutoffs, assigning a maximum of six points: platelet count less than 150×109/l, LSM greater than or equal to 15 kPa, age greater than or equal to 50 years, male sex, controlled/uncontrolled viral hepatitis, or presence of steatotic liver diseases. Within 2 years, with a median follow-up of 13.7 months, patients in the high-risk group (≥4 points) had an HCC incidence of 15.6% (95% confidence interval [CI], 12.1% to 18.7%) compared with the low-risk group, at 1.7% (95% CI, 0.9% to 2.5%). Conclusions Our algorithm stratified patients into two groups: those at higher risk of developing HCC and those at lower risk. Our data provide equipoise to test the prospective utility of the algorithm with respect to clinical decisions about screening patients with ACLD for incident HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results